Kaerus Bioscience has received orphan drug and rare paediatric drug designations from the FDA for KER-0193, its lead ...

QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial ...

WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, ...